Clinical trial
Etanercept SFP in RA Patients
NCT00413452 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00413452 |
|---|---|
| Title | Etanercept SFP in RA Patients |
| Official title | Open-Label Study to Assess the Safety and Immunogenicity of Etanercept SFP When Administered to Subjects Diagnosed With Rheumatoid Arthritis. |
| Lead sponsor | Amgen, Industry |
| Collaborators | Wyeth is now a wholly owned subsidiary of Pfizer Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Rheumatoid Arthritis |
| Intervention type | Drug |
| Interventions | Etanercept |
| Enrollment | 224 |
| Start date | Dec 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Dec 19, 2006 |
| Last update posted | Feb 13, 2009 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: